You are here
ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes
YONKERS, N.Y., Nov. 01, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the Company will participate in multiple presentations at the 2nd International Symposium on Antimicrobial Hydrolytic Enzymes (The Lysin Meeting), to be held from November 6 – 8, 2018, in New York, NY.
ContraFect will discuss lead lysin product candidate, CF-301 (exebacase), currently being studied in a Phase 2 clinical study as a potential novel therapy to improve clinical outcomes for patients with Staphylococcus aureus (Staph aureus) bacteremia including endocarditis.
“As the leading biotechnology company developing lysin therapeutics, we are pleased to return this year to The Lysin Meeting as both a leading sponsor and participant and to have organized the 'Pathway from Bench to Bedside' session,” said Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer. “We are encouraged by the progress of our Phase 2 study of exebacase and are excited that upcoming data in this program will continue to be the vanguard for our broader pipeline of lysin candidates.”
Presentation Title: Lysin CF-301 activates latent host factors in human blood to potentiate bacteriolysis
Presenter: Raymond Schuch, Ph.D., the Company’s Vice President of Research
Session Title: Session One: Gram-Positive Lysins as Therapeutics
Time and Date: 10:00 – 10:25 am ET, Tuesday, November 6, 2018
Presentation Title: In vivo pharmacology
Presenter: Dario Lehoux, Ph.D., Consultant to the Company, Pre-Clinical Development
Session Title: Session Six: The Pathway from Bench to Bedside
Time and Date: 10:05 – 10:25 am ET, Thursday, November 8, 2018
Presentation Title: Clinical Development – CF-301 (exebacase) – A case study
Presenter: Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer
Session Title: Session Six: The Pathway from Bench to Bedside
Time and Date: 10:25 – 10:45 am ET, Thursday, November 8, 2018
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza. ContraFect’s lead product candidate, CF-301, is currently in a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S. ContraFect is also conducting research focused on the discovery of lysins to target Gram-negative bacteria.
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, whether CF-301 has the potential to be a novel therapy for Staph aureus bacteremia including endocarditis, whether exebacase continues to demonstrate encouraging preclinical and clinical data, the progress of our Phase 2 study of exebacase, whether upcoming data in this program will continue to be the vanguard for ContraFect’s broader pipeline of lysin candidates, presentation details, our ability to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses, whether our initial product candidates can treat antibiotic-resistant infections such as MRSA and influenza, and our ability to discover new lysins targeting Gram-negative bacteria. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts:
Stern Investor Relations